The laboratory creates a center to develop painkillers
Barcelona Science Park
Laboratorios Esteve has opened a center to develop new analgesics in the Barcelona Science Park (PCB), a draft joint research with scientists PCB bringing to 20 million euros annual spending on R & D that the family pharmaceutical group performs in the park.
José Miguel Vela, director of drug development and clinical development group said the new unit will be co-directed by Miriam Royo, head of the platform combinatorial chemistry PCB, and will initially have four investigators, although the forecast is to continue growing in staff and new projects. The firm, he said, already has 2,300 m2 of offices, animalario and laboratories in the Science Park, where its center of drug development in 2012 moved “For years we opted to boost R & D open and collaborative, so now we make half of our research outside the group. ”
The new joint unit aims to design and synthesize new compounds to develop, effective treatments for chronic pain conditions, a medical unmet need.
Esteve has already begun to achieve results from its location in the Parc, and Vela highlighted the collaboration agreement with Enantia, a spin-off of the University of Barcelona in which there are 8 chemical group working on technology co-crystallization. The company also has an agreement with VSY Biotechnology to develop specialized products in ophthalmic surgery and more specifically in cataract operations.
Vela said that among the R + D major collaborative group are that performed at the University of Santiago de Compostela, focused on developing robotic methods to determine the pharmacological activity in vitro of potential new medicines, which have 6 researchers . Esteve has another mixed unit with the Catalan Institute of Chemical Research of Tarragona, and the Universitat Pompeu Fabra.
Esteve closed last year with consolidated sales 870 million euros, 3.8% more than the previous year, of which 63% were exports. The firm gets 40% of its revenue from its generics division, 30% of pharmacy and 30% of fine chemicals.
EXECUTIVE CHAUFFEUR BARCELONA 